Table 2.
Clinical trials based on potential NK cell checkpoint inhibitors in cancer.
| Registry | Disease | Intervention | Phase | Status | Enrollment | Sponsors and collaborators | |
|---|---|---|---|---|---|---|---|
| TIGIT | NCT03119428 | Locally advanced cancer, metastatic cancer | OMP-313M32/Nivolumab | I | Active | 30 | OncoMed Pharmaceuticals, Inc. |
| NCT03563716 | Non-small cell lung cancer | MTIG7192A/Atezolizumab | II | Active | 120 | Genentech, Inc. | |
| NCT03628677 | Non-small Cell Lung Cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, breast cancer, colorectal cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, merkel cell carcinoma, gastroesophageal cancer |
AB154/AB122 | I | Recruiting | 242 | Arcus Biosciences, Inc. | |
| NCT02794571 | Advanced/metastatic tumors | Atezolizumab/MTIG7192A | I | Recruiting | 300 | Genentech, Inc. | |
| KIR | NCT01750580 | CANCER, NOS | Lirilumab/Ipilimumab | I | Completed | 22 | Bristol-Myers Squibb |
| NCT01714739 | CANCER, NOS | Lirilumab/Nivolumab/Ipilimumab | I/II | Active | 337 | Bristol-Myers Squibb | |
| NCT03203876 | Advanced cancer | Lirilumab/Nivolumab/Ipilimumab | I | Active | 21 | Bristol-Myers Squibb Ono Pharmaceutical Co.Ltd |
|
| NCT01222286 | Smoldering multiple myeloma | IPH2101 | II | Completed | 30 | Innate Pharma | |
| NCT00999830 | Multiple myeloma | IPH2101 | II | Completed | 27 | Innate Pharma | |
| NCT00552396 | Multiple myeloma | Anti-KIR (1-7F9) | I | Completed | 32 | Innate Pharma | |
| NCT01256073 | Acute myeloid leukemia | IPH2101 | I | Completed | 21 | Innate Pharma | |
| NCT01687387 | Acute myeloid leukemia | IPH2102 | II | Completed | 152 | Innate Pharma | |
| NCT02481297 | Leukemia, chronic lymphocytic leukemia, lymphocytic leukemia | Lirilumab/Rituximab | II | Active | 8 | M.D. Anderson Cancer Center ristol-MyersSquibb |
|
| NCT02593045 | Cutaneous T-Cell lymphoma | IPH4102 | I | Active | 60 | Innate Pharma | |
| NCT03902184 | Lymphoma, mycosis fungoides/sezary syndrome | IPH4102 + Gemcitabine + Oxaliplatin | II | Recruiting | 250 | Innate Pharma | |
| TIM-3 | NCT03489343 | Metastatic cancer, solid tumor, lymphoma | Sym023 | I | Recruiting | 48 | Symphogen A/S |
| NCT02817633 | Advanced or metastatic solid tumors | TSR-022/TSR-042/TSR-033 | I | Recruiting | 819 | Tesaro, Inc. | |
| NCT03680508 | Adult primary liver cancer, advanced adult primary liver cancer, localized unresectable adult primary liver cancer | TSR-022 + TSR-042 | II | Not yet recruiting | 42 | University of Hawaii | |
| NCT03311412 | Metastatic cancer, solid tumor, lymphoma | Sym021/Sym022/Sym023 | I | Recruiting | 102 | Symphogen A/S | |
| NCT03099109 | Solid tumor | LY3321367/LY3300054 | I | Recruiting | 196 | Eli Lilly and Company | |
| NCT03744468 | Locally advanced or metastatic solid tumors | BGB-A425/tislelizumab | I/II | Recruiting | 162 | BeiGene | |
| NCT03961971 | Glioblastoma multiforme | MBG453 | I | Not yet recruiting | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NovartisPharmaceuticals |
|
| NCT03066648 | Leukemia, myelodysplastic syndromes, preleukemia, bone marrow diseases, hematologic diseases | Decitabine/PDR001/MBG453 | I | Recruiting | 175 | Novartis Pharmaceuticals |
|
| NCT02608268 | Advanced malignancies | MBG453/PDR001 | I/II | Recruiting | 250 | Novartis Pharmaceuticals |
|
| LAG-3 | NCT03489369 | Metastatic cancer, solid tumor, lymphoma | Sym022 | I | Recruiting | 30 | Symphogen A/S |
| NCT03311412 | Metastatic cancer, solid tumor, lymphoma | Sym021/Sym022/Sym023 | I | Recruiting | 102 | Symphogen A/S | |
| NCT02061761 | Hematologic neoplasms | BMS-986016/BMS-936558 | I/II | Recruiting | 132 | Bristol-Myers Squibb | |
| NCT02966548 | Cancer | Relatlimab/Nivolumab | I | Recruiting | 45 | Bristol-Myers Squibb Ono Pharmaceutical Co.Ltd |
|
| NCT01968109 | Neoplasms by site | Relatlimab/Nivolumab/BMS-986213 | I/II | Recruiting | 2000 | Bristol-Myers Squibb | |
| NCT03459222 | Advanced cancer | Relatlimab/Nivolumab/BMS-986205/Ipilimumab | I/II | Recruiting | 230 | Bristol-Myers Squibb | |
| NCT02658981 | Glioblastoma, gliosarcoma, recurrent brain neoplasm | BMS 986016/Anti-PD-1/Anti-CD137 | I | Recruiting | 100 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) Bristol-MyersSquibb |
|
| NCT03044613 | Gastric cancer, esophageal cancer, gastroesophageal cancer | Nivolumab/Relatlimab/Carboplatin/Paclitaxel/Radiation | I | Recruiting | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-MyersSquibb |
|
| NCT03623854 | Chordoma, locally advanced chordoma, metastatic chordoma, unresectable chordoma | Nivolumab/Relatlimab | II | Recruiting | 20 | Jonsson Comprehensive Cancer Center National Cancer Institute(NCI) |
|
| NCT03493932 | Glioblastoma | Nivolumab/BMS-986016 | I | Recruiting | 20 | National Institute of Neurological Disorders and Stroke (NINDS) |
|
| NCT03743766 | Melanoma | Relatlimab/Nivolumab | II | Recruiting | 42 | John Kirkwood Bristol-MyersSquibb |
|
| NCT00351949 | Stage IV renal cell carcinoma | IMP321 | I | Completed | 24 | Immutep S.A, Umanis | |
| NCT03252938 | Solid tumors, peritoneal carcinomatosis | IMP321/Avelumab | I | Recruiting | 50 | IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest |
|
| NCT00349934 | Metastatic breast cancer | IMP321 | I | Completed | 33 | Immutep S.A, Umanis | |
| NCT03625323 | Non-small cell lung cancer, squamous cell carcinoma of head and neck | Eftilagimod alpha/Pembrolizumab | II | Recruiting | 109 | Immutep S.A, Merck Sharp & Dohme Corp. | |
| NCT02614833 | Stage IV breast adenocarcinoma | IMP321/Paclitaxel | II | Active | 241 | Immutep S.A. | |
| NCT02676869 | Stage IV and stage III melanoma | IMP321/Pembrolizumab | I | Active | 24 | Immutep Australia Pty. Ltd. | |
| NKG2A | NCT02921685 | Hematological malignancy | Monalizumab (IPH2201) | I | Recruiting | 18 | Institut Paoli-Calmettes InnatePharma |
| NCT02557516 | Chronic lymphocytic leukemia | Monalizumab | I/II | Active | 22 | Innate Pharma | |
| NCT02459301 | Gynecologic cancer | IPH2201 | I | Active | 59 | Canadian Cancer Trials Group | |
| NCT02643550 | Head and neck neoplasms | Monalizumab/Cetuximab/ Anti-PD-L1 | I/II | Recruiting | 140 | Innate PharmaAstraZeneca | |
| NCT02671435 | Advanced solid tumors | Durvalumab (MEDI4736)/Monalizumab (IPH2201) | I/II | Recruiting | 501 | MedImmune LLC | |
| NCT03822351 | Unresectable stage III non-small cell lung cancer | Durvalumab/Monalizumab/ Oleclumab | II | Recruiting | 300 | MedImmune LLC | |
| NCT03833440 | Non-small cell lung cancer | Durvalumab (MEDI4736)/Monalizumab/ Oleclumab (MEDI9447)/AZD6738 | II | Not yet recruiting | 120 | Assistance Publique Hopitaux De Marseille | |
| NCT02331875 | Squamous cell carcinoma of the oral cavity | IPH2201 | I/II | Terminated | 3 | Innate Pharma | |
| NCT03088059 | Squamous cell carcinoma of head and neck | Afatinib/Palbociclib/ IPH2201/Durvalumab/ Niraparib/BAY1163877 |
II | Recruiting | 340 | European Organization for Research and Treatment of Cancer |